Biologics for plaque psoriasis ranked for efficacy
But it's debatable whether small differences among them are clinically meaningful, say commentators
Two biologics for plaque psoriasis, available on the PBS, feature in an “elite group” of four that rank highest in terms of short-term efficacy, expert commentators say.
The four biologics — brodalumab, guselkumab, ixekizumab and risankizumab-rzaa — achieved the highest proportion of 90% improvement in the Psoriasis Area and Severity Index (PASI 90) scores at 10-16 weeks in a network meta-analysis that examined all treatments for the condition licensed by the US FDA.
